secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001104659-25-048183
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva Biologics Q1 2025: VCN-01 Ph2b meets endpoints; cash runway extended into Q1 2026
--------------------------------------------------------------------------------

- VCN-01 plus gemcitabine/nab-paclitaxel increased OS, PFS, DOR in mPDAC vs SoC alone in Phase 2b.
- Two doses of VCN-01 showed greater OS benefit than one dose in patients receiving ≥4 chemo cycles.
- Closed public offering of 6,818,180 shares and warrants at $1.10/unit, gross proceeds ~$7.5M.
- Cash balance post-offering $14.1M, extending runway into Q1 2026.
- Q1 2025 G&A $1.4M (-25% YoY); R&D $3.0M (-14% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925048183/0001104659-25-048183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925048183/tm2514864d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-048183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer